126 related articles for article (PubMed ID: 33119145)
21. AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
Cell Death Differ; 2020 Jul; 27(7):2081-2098. PubMed ID: 31919461
[TBL] [Abstract][Full Text] [Related]
22. Investigating the utility of human melanoma cell lines as tumour models.
Vincent KM; Postovit LM
Oncotarget; 2017 Feb; 8(6):10498-10509. PubMed ID: 28060736
[TBL] [Abstract][Full Text] [Related]
23. A genomic screen identifies TYRO3 as a MITF regulator in melanoma.
Zhu S; Wurdak H; Wang Y; Galkin A; Tao H; Li J; Lyssiotis CA; Yan F; Tu BP; Miraglia L; Walker J; Sun F; Orth A; Schultz PG; Wu X
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17025-30. PubMed ID: 19805117
[TBL] [Abstract][Full Text] [Related]
24. TYRO3-mediated regulation of MITF: a novel target in melanoma?
Rudloff U; Samuels Y
Pigment Cell Melanoma Res; 2010 Feb; 23(1):9-11. PubMed ID: 19843245
[No Abstract] [Full Text] [Related]
25. CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.
Gioia R; Trégoat C; Dumas PY; Lagarde V; Prouzet-Mauléon V; Desplat V; Sirvent A; Praloran V; Lippert E; Villacreces A; Leconet W; Robert B; Vigon I; Roche S; Mahon FX; Pasquet JM
J Pathol; 2015 Sep; 237(1):14-24. PubMed ID: 25965880
[TBL] [Abstract][Full Text] [Related]
26. SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells.
Flammiger A; Besch R; Cook AL; Maier T; Sturm RA; Berking C
J Invest Dermatol; 2009 Apr; 129(4):945-53. PubMed ID: 18923447
[TBL] [Abstract][Full Text] [Related]
27. BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells.
Ellmann L; Joshi MB; Resink TJ; Bosserhoff AK; Kuphal S
Lab Invest; 2012 Dec; 92(12):1788-800. PubMed ID: 23069940
[TBL] [Abstract][Full Text] [Related]
28. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
30. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
[TBL] [Abstract][Full Text] [Related]
31. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
32. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL.
Pietrobono S; Anichini G; Sala C; Manetti F; Almada LL; Pepe S; Carr RM; Paradise BD; Sarkaria JN; Davila JI; Tofani L; Battisti I; Arrigoni G; Ying L; Zhang C; Li H; Meves A; Fernandez-Zapico ME; Stecca B
Nat Commun; 2020 Nov; 11(1):5865. PubMed ID: 33203881
[TBL] [Abstract][Full Text] [Related]
33. Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma.
Flem-Karlsen K; McFadden E; Omar N; Haugen MH; Øy GF; Ryder T; Gullestad HP; Hermann R; Mælandsmo GM; Flørenes VA
Mol Cancer Ther; 2020 Mar; 19(3):895-905. PubMed ID: 31871265
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
Song X; Akasaka H; Wang H; Abbasgholizadeh R; Shin JH; Zang F; Chen J; Logsdon CD; Maitra A; Bean AJ; Wang H
J Biol Chem; 2020 Feb; 295(8):2348-2358. PubMed ID: 31959629
[TBL] [Abstract][Full Text] [Related]
35. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
36. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
37. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
[TBL] [Abstract][Full Text] [Related]
38. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
40. The WNT/Beta-catenin pathway in melanoma.
Larue L; Delmas V
Front Biosci; 2006 Jan; 11():733-42. PubMed ID: 16146765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
